Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) has successfully completed two Phase III clinical trials (SYMPHONY-1 and SYMPHONY-2) for HTD1801 in patients with Type 2 Diabetes Mellitus (T2DM), demonstrating positive efficacy and safety results over a 52-week period [1][2] Group 1: Clinical Trial Results - The 52-week data from the two Phase III clinical studies confirm the durability of HTD1801's efficacy, highlighting its long-term comprehensive clinical benefits for T2DM patients [1] - The proportion of patients achieving HbA1c targets (HbA1c < 7.0%) remained stable at week 52 during the double-blind period [1] - HTD1801 showed sustained efficacy in lipid reduction, with significant decreases in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) [1] Group 2: Inflammatory Markers and Cardiovascular Benefits - Long-term treatment with HTD1801 also led to sustained reductions in inflammatory markers closely related to cardiovascular events and clinical outcomes in T2DM patients, including gamma-glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hs-CRP) [1] Group 3: Safety and Tolerability - HTD1801 demonstrated good safety and tolerability during long-term treatment, consistent with double-blind results, indicating that extending the treatment period does not increase the types or severity of adverse events for patients [2]
君圣泰医药-B：全球首创抗炎代谢调节剂HTD1801完成2型糖尿病III期临床研究 展现持续52周的综合获益与安全性优势